156 related articles for article (PubMed ID: 24253898)
1. Silencing MAP3K1 expression through RNA interference enhances paclitaxel-induced cell cycle arrest in human breast cancer cells.
Hu P; Huang Q; Li Z; Wu X; Ouyang Q; Chen J; Cao Y
Mol Biol Rep; 2014 Jan; 41(1):19-24. PubMed ID: 24253898
[TBL] [Abstract][Full Text] [Related]
2. A combination of paclitaxel and siRNA-mediated silencing of Stathmin inhibits growth and promotes apoptosis of nasopharyngeal carcinoma cells.
Wu Y; Tang M; Wu Y; Weng X; Yang L; Xu W; Yi W; Gao J; Bode AM; Dong Z; Cao Y
Cell Oncol (Dordr); 2014 Feb; 37(1):53-67. PubMed ID: 24306928
[TBL] [Abstract][Full Text] [Related]
3. [Silencing RRM1 gene reverses paclitaxel resistance in human breast cancer cell line MCF- 7/R by inducing cell apoptosis].
Tian N; Zhou L; Yang D; Wu H; Ma Y; Lü L; Wu S
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Mar; 39(3):304-312. PubMed ID: 31068300
[TBL] [Abstract][Full Text] [Related]
4. [Effect of down-regulation of Oct4 gene on biological characteristics of MDA-MB-231 breast cancer stem cells].
Zhonghua Zhong Liu Za Zhi; 2015 Apr; 37(4):251-7. PubMed ID: 26462888
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
6. Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells.
Choi YH; Yoo YH
Oncol Rep; 2012 Dec; 28(6):2163-9. PubMed ID: 23023313
[TBL] [Abstract][Full Text] [Related]
7. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
Hu K; Law JH; Fotovati A; Dunn SE
Breast Cancer Res; 2012 Feb; 14(1):R22. PubMed ID: 22309939
[TBL] [Abstract][Full Text] [Related]
8. End-binding protein 1 stimulates paclitaxel sensitivity in breast cancer by promoting its actions toward microtubule assembly and stability.
Luo Y; Li D; Ran J; Yan B; Chen J; Dong X; Liu Z; Liu R; Zhou J; Liu M
Protein Cell; 2014 Jun; 5(6):469-79. PubMed ID: 24748116
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia decreased chemosensitivity of breast cancer cell line MCF-7 to paclitaxel through cyclin B1.
Dong XL; Xu PF; Miao C; Fu ZY; Li QP; Tang PY; Wang T
Biomed Pharmacother; 2012 Feb; 66(1):70-5. PubMed ID: 22264882
[TBL] [Abstract][Full Text] [Related]
10. [Growth of breast cancer cells is inhibited in vitro by cyclin E-siRNA].
He WS; Huang T; Ren JH
Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):170-3. PubMed ID: 19615252
[TBL] [Abstract][Full Text] [Related]
11. Expression and underlying roles of IGFBP-3 in paclitaxel-treated gastric cancer SGC-7901 cells.
Huang G; Dang ZF; Dang YM; Cai W; Li Y; Chen YR; Xie XD
Asian Pac J Cancer Prev; 2014; 15(14):5741-5. PubMed ID: 25081695
[TBL] [Abstract][Full Text] [Related]
12. Tissue inhibitor of metalloproteinase-1 protects MCF-7 breast cancer cells from paclitaxel-induced apoptosis by decreasing the stability of cyclin B1.
Wang T; Lv JH; Zhang XF; Li CJ; Han X; Sun YJ
Int J Cancer; 2010 Jan; 126(2):362-70. PubMed ID: 19609944
[TBL] [Abstract][Full Text] [Related]
13. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles.
Feng Q; Yu MZ; Wang JC; Hou WJ; Gao LY; Ma XF; Pei XW; Niu YJ; Liu XY; Qiu C; Pang WH; Du LL; Zhang Q
Biomaterials; 2014 Jun; 35(18):5028-38. PubMed ID: 24680191
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of MyD88 and association with paclitaxel resistance in breast cancer.
Xiang F; Ni Z; Zhan Y; Kong Q; Xu J; Jiang J; Wu R; Kang X
Tumour Biol; 2016 May; 37(5):6017-25. PubMed ID: 26596839
[TBL] [Abstract][Full Text] [Related]
15. RNA interference targeting CHFR enhances taxol chemosensitivity in endometrial cancer cells.
Li X; Wang X; Yang Y; Xu C; Shen H
Oncol Rep; 2012 Jul; 28(1):248-54. PubMed ID: 22469813
[TBL] [Abstract][Full Text] [Related]
16. Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
Jagadish N; Fatima R; Sharma A; Devi S; Suri V; Kumar V; Suri A
Tumour Biol; 2018 May; 40(5):1010428318773652. PubMed ID: 29745297
[TBL] [Abstract][Full Text] [Related]
17. Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest.
Ling X; Bernacki RJ; Brattain MG; Li F
J Biol Chem; 2004 Apr; 279(15):15196-203. PubMed ID: 14722122
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer cells are arrested at different phases of the cell cycle following the re-expression of ARHI.
Zuo X; Qin Y; Zhang X; Ning Q; Shao S; Luo M; Yuan N; Huang S; Zhao X
Oncol Rep; 2014 May; 31(5):2358-64. PubMed ID: 24676336
[TBL] [Abstract][Full Text] [Related]
19. Reversal effects of Raloxifene on paclitaxel resistance in 2 MDR breast cancer cells.
Xu L; Lei J; Jiang D; Zhou L; Wang S; Fan W
Cancer Biol Ther; 2015; 16(12):1794-801. PubMed ID: 26529585
[TBL] [Abstract][Full Text] [Related]
20. Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel.
Zou CF; Jia L; Jin H; Yao M; Zhao N; Huan J; Lu Z; Bast RC; Feng Y; Yu Y
BMC Cancer; 2011 Jan; 11():22. PubMed ID: 21244707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
